NERV Minerva Neurosciences Inc

8.01
-0.47  -6%
Previous Close 8.48
Open 8.48
Price To Book 5.64
Market Cap 312,594,023
Shares 39,025,471
Volume 330,757
Short Ratio
Av. Daily Volume 442,449
Stock charts supplied by TradingView

NewsSee all news

  1. Cardiva Medical Appoints Jeri Hilleman to the Company's Board of Directors

    Company to Present at the 38th Annual J.P. Morgan Healthcare Conference Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced the appointment of medical device expert Jeryl ("Jeri")

  2. Minerva Neurosciences Announces Completion of Patient Screening in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

    WALTHAM, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the

  3. Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder

    MIN-117 study did not meet its primary (MADRS) and key secondary (HAM-A) endpointsMIN-117 was generally well-tolerated with a safety profile comparable to placeboCompany to host conference call at 5:00 p.m. today

  4. SI-BONE Names Jeryl ("Jeri") Hilleman to Board of Directors

    SANTA CLARA, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today

  5. Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 21, 2019

    WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data noted quantitative advantage but no statistical separation between two arms. Company noted trial was not designed to detect statistical significance.
MIN-202 (seltorexant) vs quetiapine
Major Depressive Disorder
Phase 2b data May 13, 2019 noted p-value was 0.083.
MIN-202 (seltorexant)
Major Depressive Disorder
Phase 2b data failed to meet endpoints - December 18, 2019. Development to be discontinued in MDD.
MIN-117
Major Depressive Disorder
Phase 3 data due 2Q 2020.
Roluperidone (MIN-101)
Schizophrenia
Phase 2b data June 24, 2019 met primary endpoint.
MIN-202 (seltorexant)
Primary insomnia

Latest News

  1. Cardiva Medical Appoints Jeri Hilleman to the Company's Board of Directors

    Company to Present at the 38th Annual J.P. Morgan Healthcare Conference Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced the appointment of medical device expert Jeryl ("Jeri")

  2. Minerva Neurosciences Announces Completion of Patient Screening in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

    WALTHAM, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the

  3. Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder

    MIN-117 study did not meet its primary (MADRS) and key secondary (HAM-A) endpointsMIN-117 was generally well-tolerated with a safety profile comparable to placeboCompany to host conference call at 5:00 p.m. today

  4. SI-BONE Names Jeryl ("Jeri") Hilleman to Board of Directors

    SANTA CLARA, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today

  5. Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 21, 2019

    WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system

  6. Minerva Neurosciences Reports Third Quarter 2019 Financial Results and Business Updates

    WALTHAM, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS)

  7. Minerva Neurosciences to Report Third Quarter 2019 Financial Results and Business Updates on November 4, 2019

    WALTHAM, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS)

  8. Minerva Neurosciences Announces Update for Three Clinical Trials

    WALTHAM, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS)

  9. Minerva Neurosciences to Host Conference Call and Live Webcast on Tuesday, October 1 at 8:30 AM ET

    WALTHAM, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS)

  10. Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone

    Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, and Minerva Neurosciences, Inc.

  11. Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone

    WALTHAM, Mass. and SOMERSET, N.Y., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat

  12. Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone

    SOMERSET, N.J. and WALTHAM, Mass., Sept. 24, 2019 /PRNewswire-PRWeb/ -- Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene

  13. Divide & Conquer, Developing New Class of Cancer Therapeutics to Disrupt Cell-to-Cell Communication, Emerges from Stealth as New Paper by Co-Founder is Published in Nature

    $13 Million Series A Financing from Medicxi Development pipeline based on co-founders' research into disconnecting tumour cell networks Initial focus on glioblastoma, expanding to other solid tumours New Nature